Short Interest in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Grows By 13,466.7%

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCTGet Rating) saw a large increase in short interest in May. As of May 15th, there was short interest totalling 81,400 shares, an increase of 13,466.7% from the April 30th total of 600 shares. Based on an average trading volume of 216,200 shares, the days-to-cover ratio is presently 0.4 days.

Provectus Biopharmaceuticals Stock Performance

Shares of Provectus Biopharmaceuticals stock opened at $0.13 on Friday. The company has a 50-day moving average of $0.15 and a 200 day moving average of $0.13. Provectus Biopharmaceuticals has a 1 year low of $0.03 and a 1 year high of $0.19.

Provectus Biopharmaceuticals Company Profile

(Get Rating)

Provectus Biopharmaceuticals, Inc is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treat several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer.

Featured Stories

Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with's FREE daily email newsletter.